By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mundipharma AG 

St. Alban-Rheinweg 74

Basel    CH-4006  Switzerland
Phone: 41-61-2051112 Fax: 41-61-2051109



Company News
Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma 8/14/2017 5:53:21 AM
Mundipharma AG And Helsinn Expand Exclusive Licensing And Distribution Agreements For Leading Anti-emetic Products In Middle East, Africa, Latin America And Indonesia 2/14/2017 8:39:45 AM
Mundipharma Research Release: Company Becomes Latest Life Sciences Organization To Implement New User Experience Version Of CSC’s FirstDoc RIM Application 1/18/2017 7:52:40 AM
Mundipharma AG Signs New Deal With Vectura Limited For Global Development And Commercialization Of Inhaled Triple Therapy VR2076 For The Treatment Of Asthma And COPD 12/27/2016 9:16:59 AM
Mundipharma AG Announces EU Regulatory Submission For Nyxoid 11/2/2016 9:34:27 AM
Mundipharma AG And Orexo (ORXOF) Announce EU Regulatory Submission For Zubsolv 10/4/2016 12:36:01 PM
Manchester City Nets Key Partnership With Mundipharma AG 10/4/2016 10:50:52 AM
Mundipharma AG Obtains Global (Ex-US) Rights To Orexo (ORXOF)’s Opioid Dependence Treatment Zubsolv (Buprenorphine And Naloxone) 6/30/2016 11:38:55 AM
Mundipharma AG Release: Multinational ADOPT Study Seeks Further Improvement In Management Of Oral Mucositis 6/28/2016 11:31:41 AM
Helsinn Group Signs Exclusive Agreement With Mundipharma AG For The Distribution And Licence Of Anamorelin In Northern Europe Countries 2/16/2016 9:24:55 AM